Chronic kidney disease (CKD) has emerged as a global public health problem. Although the incidence and prevalence of CKD vary from one country to another, the estimated worldwide prevalence is 8–16%. The complications associated with CKD include progression to end-stage renal disease (ESRD), mineral and bone disorders, anaemia, cognitive decline and elevated all-cause and cardiovascular (CV) mortality. As a result of progressive nephron loss, patients with late-stage CKD are permanently exposed to uraemic toxins. These toxins have been classified into three groups as a function of the molecular mass: small water-soluble molecules, middle molecules and protein-bound uraemic toxins. The compounds can also be classified according to their origin (i.e. microbial or not) or their protein-binding ability. The present review will focus on the best-characterized protein-bound uraemic toxins, namely indoxylsulfate (IS), indole acetic acid (IAA) and p-cresylsulfate (PCS, a cresol metabolite). Recent research suggests that these toxins accelerate the progression of CV disease, kidney disease, bone disorders and neurological complications. Lastly, we review therapeutic approaches that can be used to decrease toxin levels.
Skip Nav Destination
Article navigation
December 2016
-
Cover Image
Cover Image
IL-13 induced actin cytoskeleton rearrangement in human podocytes. Magnification, x60, scale bar, 20μm. For more information please see pp. 2317-2327. Image provided by Chan Chang Yien.
Review Article|
October 31 2016
Protein-bound toxins: has the Cinderella of uraemic toxins turned into a princess?
Sophie Liabeuf;
Sophie Liabeuf
*INSERM U1088, Jules Verne University of Picardy, Amiens 80000, France
†Clinical Research Centre Division of Clinical Pharmacology, Amiens University Hospital, Amiens 80000, France
Search for other works by this author on:
Cédric Villain;
Cédric Villain
‡Nephrology Unit, Ambroise Paré Hospital, AP-HP, Université de Versailles Saint-Quentin en Yvelines, Boulogne-Billancourt F-92100, France
§INSERM U1018, Université de Versailles Saint-Quentin en Yvelines, Université Paris-Saclay, Villejuif 94804, France
Search for other works by this author on:
Ziad A. Massy
‡Nephrology Unit, Ambroise Paré Hospital, AP-HP, Université de Versailles Saint-Quentin en Yvelines, Boulogne-Billancourt F-92100, France
§INSERM U1018, Université de Versailles Saint-Quentin en Yvelines, Université Paris-Saclay, Villejuif 94804, France
Correspondence: Prof. Ziad A. Massy (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
May 27 2016
Revision Received:
August 29 2016
Accepted:
September 14 2016
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society
2016
Clin Sci (Lond) (2016) 130 (23): 2209–2216.
Article history
Received:
May 27 2016
Revision Received:
August 29 2016
Accepted:
September 14 2016
Citation
Sophie Liabeuf, Cédric Villain, Ziad A. Massy; Protein-bound toxins: has the Cinderella of uraemic toxins turned into a princess?. Clin Sci (Lond) 1 December 2016; 130 (23): 2209–2216. doi: https://doi.org/10.1042/CS20160393
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |